Gosset Brain-derived neurotrophic factor receptor tyrosine kinase B Overview
Brain-derived neurotrophic factor receptor tyrosine kinase B (TrkB) is a high-affinity cell surface receptor predominantly expressed in neurons of the central and peripheral nervous system. TrkB is the principal receptor for brain-derived neurotrophic factor (BDNF); upon ligand binding, TrkB dimerizes and autophosphorylates, initiating intracellular signaling through multiple pathways—including MAPK, PI3K/Akt, and PLCγ—which together regulate neuronal survival, differentiation, synaptic growth, and plasticity[1][3][4][5]. TrkB activation is essential for neurodevelopment and the response to injury, while dysregulation of BDNF/TrkB signaling is implicated in neurodegenerative and psychiatric diseases[2][4][5]. Therapies targeting TrkB aim to modulate these pathways for neuroprotection or regeneration, but clinical application faces challenges related to delivery, specificity, and safety[6].
Mechanism of Action
Agonists: Induce dimerization and autophosphorylation of the TrkB receptor, activating downstream survival and plasticity pathways (MAPK, PI3K-Akt, PLCγ). Antagonists: Block BDNF binding and receptor activation.
Biological Functions
Disease Associations
Safety Considerations
- Limited brain penetration of most drugs
- Off-target effects on other Trk receptors
- Oncogenic potential due to chronic RTK activation
- Potential for aberrant neural growth or pain sensitization
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| Phosphorylated TrkB |
| Phosphorylated downstream effectors (e.g., p-Akt, p-ERK, p-CREB) |
| BDNF serum or CSF levels (reflect activation or efficacy) |